We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

TFP Inhibitor Levels Elevated in Bleeding Tendency Patients

By LabMedica International staff writers
Posted on 11 Feb 2021
Print article
Image: The Technothrombin TGA is a thrombin generation assay (TGA) based on monitoring the formation of thrombin by means of a fluorogenic substrate upon activation of the coagulation cascade by tissue factor (Photo courtesy of Technoclone).
Image: The Technothrombin TGA is a thrombin generation assay (TGA) based on monitoring the formation of thrombin by means of a fluorogenic substrate upon activation of the coagulation cascade by tissue factor (Photo courtesy of Technoclone).
Mild to moderate bleeding disorders (MBDs) are characterized by symptoms such as epistaxis, easy bruising, or menorrhagia, but bleeding can also be severe under certain circumstances such as hemorrhage after surgery or birth.

Tissue factor (TF) pathway inhibitor (TFPI) is a pivotal anticoagulant player in hemostasis, regulating TF-induced coagulation. Among the two major isoforms, free TFPIα, primarily produced in endothelial cells, is the only anticoagulant isoform found in blood circulation.

Hematologists at the Medical University Vienna (Vienna, Austria) investigated free TFPIα in a well-characterized cohort of 620 patients with mild to moderate bleeding tendencies and its association to genetic alterations in the F5 gene. One hundred age- and sex-matched healthy controls without a clinical bleeding tendency were recruited by trained health care personnel for comparison.

Quantification of free TFPIα levels was performed in plasma samples using a standardized enzyme-linked immunosorbent assay, the Asserachrom Free TFPI-ELISA, (Stago, Asnières sur Seine, France). Thrombin generation was assessed with the commercially available kit, Technothrombin (Technoclone, Vienna, Austria). Factor V (FV) was identified by western blot analysis. DNA libraries were captured using ROCHE NimbleGen SeqCap ThromboGenomics capture baits (Roche NimbleGen, Inc, Madison, WI, USA) and sequenced using an Illumina Hiseq 4000 sequencer (Illumina, San Diego, CA, USA).

The scientists reported that TFPIα levels were higher in patients with bleeding compared with healthy controls (median 8.2 versus 7.8). A higher proportion of patients had free TFPIα levels more than or equal to the 95th percentile compared with healthy controls (odds ratio [OR], 2.82). This was pronounced in the subgroup of patients in whom no bleeding disorder could be identified (bleeding of unknown cause [BUC; n = 420]; OR 3.03) and in platelet function defects (PFDs) (n = 121; OR 3.47). An increase in free TFPIα was associated with a mild delay in thrombin generation (prolonged lag time and time to peak), but not with alterations in routinely used global clotting tests.

The authors concluded that free TFPIα is increased in patients with mild to moderate bleeding tendency and was associated with delayed thrombin generation. This could be an underlying cause or a contributor for bleeding, especially in patients with BUC and PFDs. they could neither identify new or known genetic variations in the F5 gene that are associated with neither free TFPIα levels, nor an influence of the single-nucleotide variant rs10800453 on free TFPIα levels in their patient cohort. An imbalance of natural coagulation inhibitors such as TFPIα could be an underlying cause or contributor for unexplained bleeding, which is most probably multifactorial in a majority of patients. The study was published on January 19, 2021 in the journal Blood Advances.

Related Links:
Medical University Vienna
Roche NimbleGen

Gold Supplier
Nucleic Acid Extractor (Magnetic Bead Method)
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control
COVID-19 Anitibody Test
SGTi-flex COVID-19 IgM/IgG
Silver Supplier
Nucleic Acid Extractor

Print article


Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more


view channel

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.